- Home
- TARA vs ACTU Comparison
TARA vs ACTU Comparison
Compare TARA & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARA
- ACTU
- Stock Information
- Founded
- TARA N/A
- ACTU 2015
- Country
- TARA United States
- ACTU United States
- Employees
- TARA N/A
- ACTU N/A
- Industry
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- ACTU
- Sector
- TARA Health Care
- ACTU
- Exchange
- TARA Nasdaq
- ACTU NYSE
- Market Cap
- TARA 158.2M
- ACTU 162.1M
- IPO Year
- TARA N/A
- ACTU 2024
- Fundamental
- Price
- TARA $3.72
- ACTU $7.69
- Analyst Decision
- TARA Strong Buy
- ACTU
- Analyst Count
- TARA 3
- ACTU 0
- Target Price
- TARA $22.67
- ACTU N/A
- AVG Volume (30 Days)
- TARA 270.4K
- ACTU 20.8K
- Earning Date
- TARA 03-12-2025
- ACTU 03-04-2025
- Dividend Yield
- TARA N/A
- ACTU N/A
- EPS Growth
- TARA N/A
- ACTU N/A
- EPS
- TARA N/A
- ACTU N/A
- Revenue
- TARA N/A
- ACTU N/A
- Revenue This Year
- TARA N/A
- ACTU N/A
- Revenue Next Year
- TARA N/A
- ACTU N/A
- P/E Ratio
- TARA N/A
- ACTU N/A
- Revenue Growth
- TARA N/A
- ACTU N/A
- 52 Week Low
- TARA $1.60
- ACTU $5.51
- 52 Week High
- TARA $10.48
- ACTU $11.73
- Technical
- Relative Strength Index (RSI)
- TARA 33.05
- ACTU N/A
- Support Level
- TARA $3.91
- ACTU N/A
- Resistance Level
- TARA $4.05
- ACTU N/A
- Average True Range (ATR)
- TARA 0.29
- ACTU 0.00
- MACD
- TARA -0.07
- ACTU 0.00
- Stochastic Oscillator
- TARA 0.00
- ACTU 0.00
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.